| Ytd | -10.27% | |
| 1y | -29.56% |
| Open | 3.66 | Prev Close | 3.67 | Low | 3.61 | High | 4.04 | Mkt Cap | 1.95B |
| Vol | 35.47M | Avg Vol | 17.06M | EPS | -1.16 | P/E | N/A | Forward P/E | -4.18 |
| Beta | 1.00 | Short Ratio | 8.63 | Inst. Own | 68.78% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 3.32 | 200-d Avg | 4.10 | 1yr Est | 6.64 |
RXRX News
Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities ar
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implemen
Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Eq
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and mainta
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat th
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overwe
Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded
B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and mainta
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings
ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, R
Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby,
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory
Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive int
Cathie Wood-led Ark Invest executed several significant trades on Wednesday, with notable activity i
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded th
JP Morgan analyst Eric Joseph upgrades Recursion Pharmaceuticals (NASDAQ:RXRX) from Neutral to Ov
Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive da
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductio
Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and C
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically impro
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.36) per share which missed
On Wednesday, major U.S. indices closed mixed, with the Nasdaq rising 1.1% to 23,043.38 and the S&am
Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-des
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He reco
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshapi
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 milli
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically impro